Neuropace, Inc. NPCE Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 78.3%+3.5pp | 77.2%+3.3pp | 76.8%+2.9pp | 75.7%+1.6pp | 74.8%+0.9pp | |
| Operating margin | -16.8%+6.0pp | -16.3%+10.8pp | -19.2%+11.0pp | -22.4%+12.1pp | -22.9%+15.4pp | |
| Net margin | -21.7%+7.8pp | -21.5%+12.5pp | -25.3%+11.5pp | -29.3%+12.3pp | -29.4%+16.2pp | |
| EBITDA margin | -16.5%+6.0pp | -16%+10.7pp | -18.9%+10.9pp | -22.1%+12.0pp | -22.5%+15.3pp | |
| Free cash flow margin | -10.3%+11.2pp | -11.7%+11.1pp | -17.5%+4.5pp | -18.6%+5.5pp | -21.5%+4.1pp | |
| Returns | ||||||
| Return on equity | -111.4%+17.1pp | -158.7%+30.6pp | -169.3%+45.3pp | -176.9%+15.2pp | -128.5%+22.1pp | |
| Return on assets | -20.6%+3.1pp | -21.4%+5.4pp | -23.6%+5.2pp | -25.9%+4.5pp | -23.7%+7.0pp | |
| Return on invested capital | -24%+2.6pp | -24.1%+6.3pp | -26.7%+4.9pp | -28.7%+3.3pp | -26.7%+5.3pp | |
| Efficiency | ||||||
| Asset turnover | 1×+0.1× | 1×+0.2× | 0.9×+0.2× | 0.9×+0.2× | 0.8×+0.1× | |
| Inventory turnover | 1.4×-0.3× | 1.5×-0.2× | 1.5×-0.4× | 1.6×-0.2× | 1.7×+0.1× | |
| Liquidity | ||||||
| Current ratio | 5.4×-1.2× | 5.3×-0.1× | 4.9×-0.7× | 5.5×-0.9× | 6.6×+0.2× | |
| Quick ratio | 4.3×-1.4× | 4.3×-0.2× | 3.9×-0.8× | 4.5×-1.0× | 5.7×+0.1× | |
| Cash ratio | 1×-0.9× | 1.2×+0.3× | 1.1×0.0× | 1.3×+0.3× | 1.8×+0.8× | |
| Leverage | ||||||
| Debt-to-equity | 4.9×+1.9× | 3.7×-5.4× | 3.8×-3.6× | 3.7×-3.8× | 3×-2.1× | |
| Debt-to-assets | 0.7×0.0× | 0.7×-0.1× | 0.7×-0.1× | 0.7×-0.1× | 0.7×-0.1× | |
| Interest coverage | -2.5×-0.2× | -2.2×+0.3× | -2.3×+0.3× | -2.3×+0.5× | -2.2×+0.8× | |
| Per Share | ||||||
| Book value per share | $0.43-44.4% | $0.58+111% | $0.56+67.5% | $0.59+72.7% | $0.77+52.1% | |
| Valuation | ||||||
| Market capitalization | $557.77M+63.4% | $514.27M+54.0% | $341.07M+69.6% | $352.91M+65.0% | $400.16M+13.1% | |
| Enterprise value | $612.6M+58.1% | $563.29M+43.0% | $391.48M+51.1% | $401.45M+46.2% | $446.17M+7.8% | |
| Price / sales | 5.6×+1.6× | 5.1×+1.0× | 3.6×+1.0× | 4×+1.0× | 4.7×-0.4× | |
| Price / book | 38.6×+24.5× | 27×-14.7× | 18.4×-2.1× | 18.2×-3.5× | 16.5×-8.2× | |
| EV / sales | 6.2×+1.6× | 5.6×+0.7× | 4.1×+0.7× | 4.5×+0.7× | 5.3×-0.7× | |
| Free cash flow yield | -1.8%+3.5pp | -2.3%+3.2pp | -4.9%+3.5pp | -4.7%+3.4pp | -4.5%+0.5pp | |
| Earnings yield | -3.9%+3.4pp | -4.2%+4.0pp | -7%+6.9pp | -7.4%+6.6pp | -6.2%+2.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Neuropace, Inc.'s profit margins?
- Neuropace, Inc. (NPCE) runs a 78.3% gross margin and a -16.8% operating margin, with a -21.7% net margin.
- Where do Neuropace, Inc.'s ratios come from?
- Every ratio is computed from Neuropace, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
